Sanofi and Regeneron Pharmaceuticals, Inc has recently announced that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.
Read more at Biospectrumasia
Eczema is a high impact health issue for those who suffer with it. Join us as Dr. John Lee discusses the issues and treatments that effect you and/or your patients with eczema.
More from Allergy and Asthma Network
Age plays a huge role when it comes to patients’ access to psoriasis treatment, research shows. Researchers who have examined if patients of varying ages have the same access to the most efficient psoriasis treatment, found that an age increase of 30 years resulted in an average 65 per cent reduction in likelihood of obtaining treatment with biologics.
More at Science Daily
Patients aged 2 and older have a new option for treating their mild to moderate eczema (atopic dermatitis). AD, often called eczema, is a chronic condition impacting nearly 18 million children and adults in the United States. Approximately 90 percent of people living with AD have the mild to moderate form of the condition.
Presented by James Q. Del Rosso, DO, at the SDPA 14th Annual Fall Dermatology Conference 2016, held November 2 – 6 in Las Vegas, Nevada.
Atopic dermatitis is a long-term skin disease. “Atopic” refers to a tendency to develop allergy conditions. “Dermatitis” means swelling of the skin. This publication from the NIH addresses causes, treatments and research being conducted.
More from the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases
Chronic itch is a frustrating symptom affecting millions of people with eczema. The incessant desire to itch can be so intense for eczema patients that they itch until breaking the skin, which can lead to cycles of increased inflammation, more itch, and sometimes infection. Gil Yosipovitch, MD, professor and chair of the Department of Dermatology and director of the Temple Itch Center at Temple University School of Medicine, will present information on understanding, preventing, and treating itch.
A video from the American Academy of Allergy, Asthma and Immunology